ATE366260T1 - Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen. - Google Patents

Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.

Info

Publication number
ATE366260T1
ATE366260T1 AT97941009T AT97941009T ATE366260T1 AT E366260 T1 ATE366260 T1 AT E366260T1 AT 97941009 T AT97941009 T AT 97941009T AT 97941009 T AT97941009 T AT 97941009T AT E366260 T1 ATE366260 T1 AT E366260T1
Authority
AT
Austria
Prior art keywords
activated potassium
calcium
low
potassium channels
potassium channel
Prior art date
Application number
AT97941009T
Other languages
German (de)
English (en)
Inventor
John Adelman
James Maylie
Chris Bond
Christopher Silvia
Original Assignee
Univ Oregon Health Sciences
Ica Gen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health Sciences, Ica Gen Inc filed Critical Univ Oregon Health Sciences
Application granted granted Critical
Publication of ATE366260T1 publication Critical patent/ATE366260T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT97941009T 1996-09-11 1997-09-10 Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen. ATE366260T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2645196P 1996-09-11 1996-09-11
US4005297P 1997-03-07 1997-03-07
US4523397P 1997-04-17 1997-04-17

Publications (1)

Publication Number Publication Date
ATE366260T1 true ATE366260T1 (de) 2007-07-15

Family

ID=27362774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97941009T ATE366260T1 (de) 1996-09-11 1997-09-10 Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.

Country Status (8)

Country Link
US (9) US6797486B2 (enExample)
EP (1) EP0948542B1 (enExample)
JP (5) JP4052525B2 (enExample)
AT (1) ATE366260T1 (enExample)
AU (1) AU726158B2 (enExample)
CA (1) CA2265485C (enExample)
DE (2) DE69739956D1 (enExample)
WO (1) WO1998011139A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012281B1 (en) * 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
AU2001265384A1 (en) 2000-06-06 2001-12-17 Millennium Pharmaceuticals, Inc. 52906, 33408, and 12189, potassium channel family members and uses thereof
EP1345618B1 (de) * 2000-12-28 2005-03-23 Switch Biotech Aktiengesellschaft Chlorzoxazon zur behandlung von psoriasis
US7022480B1 (en) * 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US20050250090A1 (en) * 2003-10-28 2005-11-10 Edward Kaftan Assay systems and methods for detecting molecules that interact with SK2 channels
EP1884774A1 (en) * 2006-08-03 2008-02-06 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
CN110378549B (zh) * 2019-05-31 2023-05-23 广东工业大学 一种基于fahp-熵权法的输电杆塔鸟害等级评估方法
CN121057823A (zh) * 2023-04-10 2025-12-02 耶鲁大学 体内修饰神经元以治疗和/或预防肌萎缩性侧索硬化(als)的方法
WO2025175135A1 (en) * 2024-02-15 2025-08-21 Yale University Modifying neurons to treat or prevent parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392957B (de) 1987-08-06 1991-07-25 Technoagrar Consulting Ag Verfahren zur behandlung und entsorgung von gemengen aus feststoffen und fluessigkeiten
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
CA2116280A1 (en) * 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
US5519003A (en) 1994-02-01 1996-05-21 Board Of Trustees Of The Leland Stanford Junior University WD-40-derived peptides and uses thereof
US6277978B1 (en) * 1995-12-22 2001-08-21 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
EP1012281B1 (en) 1997-07-15 2006-11-29 AstraZeneca UK Limited Human leukocyte calcium activated potassium channel polypeptide
US6165719A (en) * 1997-07-15 2000-12-26 The Regents Of The University Of California hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target
WO1999025347A2 (en) 1997-11-14 1999-05-27 Neurosearch A/S Chemical compounds having ion channel blocking activity for the treatment of immune dysfunction

Also Published As

Publication number Publication date
US6828420B2 (en) 2004-12-07
US6828122B2 (en) 2004-12-07
EP0948542B1 (en) 2007-07-04
JP2004024268A (ja) 2004-01-29
DE69737889D1 (de) 2007-08-16
AU4266097A (en) 1998-04-02
JP2006320333A (ja) 2006-11-30
AU726158B2 (en) 2000-11-02
CA2265485A1 (en) 1998-03-19
EP0948542A4 (en) 2004-04-14
US7026451B2 (en) 2006-04-11
DE69737889T2 (de) 2008-03-13
US20020155531A1 (en) 2002-10-24
WO1998011139A1 (en) 1998-03-19
US20020165379A1 (en) 2002-11-07
US20030082684A1 (en) 2003-05-01
US20030082683A1 (en) 2003-05-01
JP4052525B2 (ja) 2008-02-27
US7534869B2 (en) 2009-05-19
US20050214845A1 (en) 2005-09-29
US20030105284A1 (en) 2003-06-05
US6894147B2 (en) 2005-05-17
EP0948542A1 (en) 1999-10-13
CA2265485C (en) 2006-08-01
US6828123B2 (en) 2004-12-07
JP2008092950A (ja) 2008-04-24
US6987169B2 (en) 2006-01-17
JP4052582B2 (ja) 2008-02-27
JP2000514310A (ja) 2000-10-31
US20020192757A1 (en) 2002-12-19
US6692937B2 (en) 2004-02-17
US20030044910A1 (en) 2003-03-06
DE69739956D1 (de) 2010-09-16
JP2004065264A (ja) 2004-03-04
US20030040048A1 (en) 2003-02-27
US6797486B2 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
ATE218708T1 (de) Elektrochemischer affinitätsassay
DK1015586T3 (da) TIE-receptortyrosinkinaseligandhomologer
FR10C0025I1 (enExample)
BR9910332A (pt) Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição
ATE327329T1 (de) Tie ligand-homologuen
AU3000701A (en) Method and device for detecting and quantifying biomolecules
DE69730820D1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
ATE273956T1 (de) Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
DK0539477T3 (da) Fremgangsmåde til forstærkning af emissionssignalet af en luminescerende forbindelse
AU2001268449A1 (en) Toxicity typing using liver stem cells
ID24876A (id) Senyawa-senyawa indola tersubstitusi-2,3 sebagai penghambat cox-2
SE0003285D0 (sv) Kodare
DE69737889D1 (de) Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.
DK1058738T3 (da) Fremgangsmåde til screening, baseret på fluorescens-polarisering
ITRM990539A0 (it) Sistema di servizi di mobilita', in particolare per zone di concentramento.
DE69920487D1 (de) Tau als marker für frühe schäden des zentralen nervensystems
TR199900430T2 (xx) �kameli 1,2,3,4-tetrahidro-2-dibenzofuranaminler ve 2-aminosiklohepta$b] benzofuranlar.
IS2530B (is) Aðferð til að greina prótín-prótín víxlverkun
WO2002077285A3 (en) Methods of determining the presence of polynucleotides employing amplification
WO2004078783A3 (en) Enzymes involved in apoptosis
EP0970192A4 (en) NUCLEIC ACID CODING THE ALGU PROTEIN OF M. TUBERCULOSIS.
EP1892252A3 (en) Intermediate conductance, calcium-activated potassium channels and uses thereof
EE200100234A (et) PRV-1-geen ja selle kasutamine
ATE329035T1 (de) Cytoplasmische tyrosin kinase
WO2000017225A3 (en) A small protein that interacts with a ribonucleotide reductase subunit and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties